ContraFect Corp (CFRX) Expected to Announce Earnings of -$0.10 Per Share

Brokerages predict that ContraFect Corp (NASDAQ:CFRX) will post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ContraFect’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.09). ContraFect posted earnings of ($0.15) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that ContraFect will report full-year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.32). For the next fiscal year, analysts forecast that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow ContraFect.

Institutional investors have recently modified their holdings of the company. Birchview Capital LP boosted its position in shares of ContraFect by 56.5% during the 3rd quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after acquiring an additional 410,000 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of ContraFect during the 3rd quarter valued at about $2,886,000. Finally, Fosun International Ltd acquired a new stake in shares of ContraFect during the 3rd quarter valued at about $9,435,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

Shares of ContraFect (CFRX) remained flat at $$1.19 during trading on Wednesday. 42,570 shares of the stock traded hands, compared to its average volume of 164,289. ContraFect has a fifty-two week low of $0.80 and a fifty-two week high of $2.50. The firm has a market capitalization of $87.28, a price-to-earnings ratio of -6.26 and a beta of -0.85.

COPYRIGHT VIOLATION NOTICE: “ContraFect Corp (CFRX) Expected to Announce Earnings of -$0.10 Per Share” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit